Omicron: What to know about this new COVID-19 variant? - By Dr. Preeti Parmar

Speciality: Infectious diseases


Speaker:

Dr. Preeti Parmar | Infedis Health

Description:

A warm welcome to all the medical professionals in this interesting session on Omicron: What to know about this new COVID-19 variant? - By Dr. Preeti Parmar
Dr. Preeti Parmar provides a comprehensive overview of Omicron, a new COVID-19 variant that has become a significant concern globally. Identified first in South Africa in late 2021, Omicron is notable for its extensive

mutations in the spike protein, which impact the virus's transmissibility and immune evasion capabilities.
Omicron's high number of mutations has made it more transmissible than previous variants. Dr. Parmar explains that this has led to rapid increases in case numbers worldwide, even in populations with high vaccination rates. While early data suggests that Omicron may result in milder illness compared to the Delta variant, its enhanced spread poses substantial risks, especially to healthcare systems already burdened by the pandemic.


Vaccination remains a key strategy in combating Omicron. Dr. Parmar highlights that booster doses significantly improve protection against this variant, reinforcing the need for booster
campaigns. Moreover, she stresses the importance of maintaining other public health measures such as mask-wearing, social distancing, and regular testing to control its spread.
Therefore, get an overall knowledge of omicron: what to know about this new covid-19 variant? - By Dr. Preeti Parmar
 

See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study opens up possibility of bespoke prostate cancer treatment

2.

Why Encouragement May Not Improve Motivation in Depression

3.

Study Finds Actionable Mutations in Brain Mets of Breast Cancer Patients

4.

A person's susceptibility to papillary thyroid cancer may be determined by variations in telomere lengthening genes.

5.

Pirtobrutinib May Be Beneficial in Follicular Lymphoma with Severe Pretreatment.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot